Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sunil Narula"'
Autor:
Benjamin A. Derman, Ankit Kansagra, Jeffrey Zonder, Andrew T. Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej J. Jakubowiak
Publikováno v:
JAMA oncology. 8(9)
ImportanceTreatment of newly diagnosed multiple myeloma (NDMM) with a quadruplet regimen consisting of a monoclonal antibody, proteasome inhibitor, immunomodulatory imide, and corticosteroid has been associated with improved progression-free survival
Autor:
Hedy L. Kindler, Blase N. Polite, Chih-Yi Liao, Theodore Karrison, Yuan Ji, Murtuza Rampurwala, Sunil Narula, Paul Chang, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Oliver S. Eng, D. Kyle Hogarth, Uzma D. Siddiqui, John Hart, Shu-Yuan Xiao, Namrata Setia, Lindsay Alpert, Natalie Reizine, Bryan F. Peterson, Leah M. Chase, Samantha Lomnicki, Stephanie Moya, Daniel V.T. Catenacci
Supplementary tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e0a1ced8f425acfcbaa028910185a2
https://doi.org/10.1158/2159-8290.22535693.v1
https://doi.org/10.1158/2159-8290.22535693.v1
Autor:
Hedy L. Kindler, Blase N. Polite, Chih-Yi Liao, Theodore Karrison, Yuan Ji, Murtuza Rampurwala, Sunil Narula, Paul Chang, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Oliver S. Eng, D. Kyle Hogarth, Uzma D. Siddiqui, John Hart, Shu-Yuan Xiao, Namrata Setia, Lindsay Alpert, Natalie Reizine, Bryan F. Peterson, Leah M. Chase, Samantha Lomnicki, Stephanie Moya, Daniel V.T. Catenacci
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were sup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41f155c561001c259ea2dbc259cd251f
https://doi.org/10.1158/2159-8290.c.6547916.v1
https://doi.org/10.1158/2159-8290.c.6547916.v1
Autor:
Hedy L. Kindler, Blase N. Polite, Chih-Yi Liao, Theodore Karrison, Yuan Ji, Murtuza Rampurwala, Sunil Narula, Paul Chang, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Oliver S. Eng, D. Kyle Hogarth, Uzma D. Siddiqui, John Hart, Shu-Yuan Xiao, Namrata Setia, Lindsay Alpert, Natalie Reizine, Bryan F. Peterson, Leah M. Chase, Samantha Lomnicki, Stephanie Moya, Daniel V.T. Catenacci
Supplmentary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::334c22bf17cef32bdb8faf4686f3c642
https://doi.org/10.1158/2159-8290.22535690
https://doi.org/10.1158/2159-8290.22535690
Autor:
Hedy L. Kindler, Blase N. Polite, Chih-Yi Liao, Theodore Karrison, Yuan Ji, Murtuza Rampurwala, Sunil Narula, Paul Chang, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Oliver S. Eng, D. Kyle Hogarth, Uzma D. Siddiqui, John Hart, Shu-Yuan Xiao, Namrata Setia, Lindsay Alpert, Natalie Reizine, Bryan F. Peterson, Leah M. Chase, Samantha Lomnicki, Stephanie Moya, Daniel V.T. Catenacci
Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ecf9d0ff43d9273e3067fea004435f5
https://doi.org/10.1158/2159-8290.22535696
https://doi.org/10.1158/2159-8290.22535696
Autor:
Leah Chase, Namrata Setia, Theodore Karrison, Samantha Lomnicki, D. Kyle Hogarth, Murtuza Rampurwala, Oliver S. Eng, Stephanie Moya, Blase N. Polite, Yuan Ji, Hedy L. Kindler, Bryan Peterson, Lindsay Alpert, Paul J. Chang, Daniel V.T. Catenacci, Natalie Reizine, John Hart, Uzma D. Siddiqui, Kiran K. Turaga, Chih-Yi Liao, Shu-Yuan Xiao, Mitchell C. Posner, Kevin K. Roggin, Sunil Narula
Publikováno v:
Cancer discovery, vol 11, iss 2
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and Significance:This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and ma
Autor:
Andrzej Jakubowiak, Bernadette Libao, Sunil Narula, Evangelia Andreatos, Brittany Wolfe, Jeffrey A. Zonder, Daniel Juergens, Ankit Kansagra, David L. Grinblatt, Michael R. Bishop, Ken Jiang, Amanda McIver, Jagoda Jasielec, Benjamin A. Derman, Luis Alcantar, Shayan Rayani, Theodore Karrison, Andrew T. Stefka, Sarah Major, Megan Whelan
Publikováno v:
Journal of Clinical Oncology. 39:8011-8011
8011 Background: The addition of a monoclonal antibody to triplet induction regimens in patients (pts) with MM with intent for autologous stem cell transplant (ASCT) has resulted in higher overall and deep response rates. In this study we are investi
Autor:
Leah Chase, Namrata Setia, Lindsay Alpert, Anthony Serritella, Daniel V.T. Catenacci, Murtuza Rampurwala, Bryan Peterson, John Hart, Uzma D. Siddiqui, Chih-Yi Liao, Theodore Karrison, Natalie Reizine, Yuan Ji, Samantha Lomnicki, Blase N. Polite, Hedy L. Kindler, Sunil Narula
Publikováno v:
Journal of Clinical Oncology. 38:4561-4561
4561 Background: Targeted therapies (tx) have had limited benefit in advanced (aGEA) due to baseline spatial (primary vs metastatic tumor PT/MT) & temporal molecular heterogeneity (BMH/TMH). We previously reported PANGEA methods & results: 35% BMH ra
Autor:
Samantha Lomnicki, Vivek N. Prachand, Kelly Moore, Mark K. Ferguson, John Hart, Chih-Yi Liao, Shu-Yuan Xiao, Robert de Wilton Marsh, Leah Chase, Lindsay Alpert, Steven Brad Maron, Namrata Setia, Kenisha Allen, Christine Racette, Mitchell C. Posner, Kevin K. Roggin, Kristin Kipping-Johnson, Bryan Peterson, Sunil Narula, Barbara Gordon, Kiran K. Turaga, Murtuza Rampurwala, Uzma D. Siddiqui, Theodore Karrison, Blase N. Polite, Hedy L. Kindler, Daniel V.T. Catenacci, Ugne Markevicius
Publikováno v:
JAMA Network Open. 3:e1921290
Importance Patients with locally advanced gastroesophageal adenocarcinoma (ie, stage ≥T3 and/or node positive) have high rates of recurrence despite surgery and adjunctive perioperative therapies, which also have high toxicity profiles. Evaluation
Autor:
Lindsay Alpert, John Hart, Sunil Narula, Bryan Peterson, Leah Chase, Namrata Setia, Murtuza Rampurwala, Kelly Moore, Ugne Markevicius, Theodore Karrison, Samantha Lomnicki, Uzma D. Siddiqui, Chih-Yi Liao, Kiran K. Turaga, Daniel V.T. Catenacci, Kristen Kipping-Johnson, Blase N. Polite, Hedy L. Kindler, Yuan Ji, Mitchell C. Posner
Publikováno v:
Journal of Clinical Oncology. 38:356-356
356 Background: 1-yr OS is ~40% for HER2- & ~55% for HER2+ advanced (aGEA). Targeted therapies (tx) have had limited benefit due to molecular heterogeneity. Methods: This phase 2a study of a personalized tx strategy (PTS) enrolled newly diagnosed aGE